NCT00001830View on ClinicalTrials.gov

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 20, 1999

Study Completion Date

May 19, 2015

Conditions
Chronic Lymphocytic LeukemiaGraft vs Host DiseaseHodgkin's DiseaseMultiple MyelomaNon Hodgkin's Lymphoma
Interventions
DRUG

Th2 cells in allo HSCTT

DRUG

Th2 Cells

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001830 - Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | Biotech Hunter | Biotech Hunter